|Bid||21.39 x 800|
|Ask||23.75 x 800|
|Day's Range||21.56 - 23.06|
|52 Week Range||13.92 - 28.18|
|Beta (5Y Monthly)||1.84|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The main aim of stock picking is to find the market-beating stocks. But in any portfolio, there will be mixed results...
Myriad Genetics (MYGN) expands Precise Oncology Solutions portfolio by adding a new biomarker test.
Investing.com -- Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: an Outperform initiation at Zions Bancorp and upgrades at KeyCorp, Greenhill, and Myriad Genetics.
Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.
Myriad Genetics ( NASDAQ:MYGN ) First Quarter 2023 Results Key Financial Results Revenue: US$181.2m (up 9.9% from 1Q...
Myriad Genetics (MYGN) delivers a year-over-year increase in first-quarter revenues, reflecting a positive volume improvement across the portfolio.
Q1 2023 Myriad Genetics Inc Earnings Call
Myriad (MYGN) delivered earnings and revenue surprises of -10.53% and 5.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) and Intermountain Precision Genomics receive the New York State Clinical Laboratory Permit to offer solid tumor testing to patients in all 50 U.S. states.
Myriad Genetics' (MYGN) latest program will increase access to affordable genetic testing. It will also aid in identifying and elevating high-risk patient care.
Myriad Genetics (MYGN), together with Illumina, will seek joint HRD companion diagnostics partnerships with pharmaceutical companies globally.
Key Insights Using the 2 Stage Free Cash Flow to Equity, Myriad Genetics fair value estimate is US$19.13 With US$22.90...
Myriad Genetics (MYGN) hereditary cancer testing volume registered strong growth in the fourth quarter. GeneSight comes up with yet another strong performance.
Q4 2022 Myriad Genetics Inc Earnings Call
Myriad (MYGN) delivered earnings and revenue surprises of 25% and 5.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics' (MYGN) significant gross margin contraction and operating loss as a result of mounting cost pressure are concerning.
Statistically speaking, long term investing is a profitable endeavour. But along the way some stocks are going to...
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Myriad Genetics' (MYGN) latest launch is expected to aid clinicians with access to tools that can assist them with turnaround times and report interpretation.
What happened Shares of Myriad Genetics (NASDAQ: MYGN), a genetic-testing and precision-medicine biotech company, were down more than 24% this week as of Thursday, according to data from S&P Global Intelligence.
Myriad Genetics (MYGN) hereditary cancer testing volume returns to growth in the third quarter. GeneSight comes up with yet another strong performance.
Myriad (MYGN) delivered earnings and revenue surprises of -375% and 9.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Myriad Genetics' (MYGN) expansion across the globe, banking on myChoiceCDx test sales, seems impressive.
Myriad Genetics' (MYGN) BRACAnalysis gained expanded coverage from MHLW to identify breast cancer patients who are eligible for treatment with Lynparza in Japan.